Skip to main content
. 2018 Jul 25;10:2241–2248. doi: 10.2147/CMAR.S166789

Table 1.

Univariate and multivariate analyses of clinicopathological and PRAF2 expression for overall survival in HCC patients (n=518)

Variables Univariate analysis
Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (<49 vs ≥49 years) 0.911 (0.765–1.086) 0.298 N/A N/A
Gender (female vs male) 1.019 (0.756–1.447) 0.900 N/A N/A
HBV (positive vs negative) 1.124 (0.878–1.438) 0.353 N/A N/A
Tumor size (≥5 vs <5 cm) 1.531 (1.235–1.897) 0.000 1.328 (1.014–1.694) 0.023
Tumor multiplicity (multiple vs single) 1.259 (1.049–1.510) 0.013 1.006 (0.814–1.242) 0.959
Tumor capsule (absent vs present) 0.694 (0.579–0.832) 0.000 0.813 (0.670–0.987) 0.037
Liver cirrhosis (no vs yes) 0.740 (0.586–0.935) 0.012 0.842 (0.658–1.078) 0.173
AFP (≥20 vs <20 ng/mL) 1.438 (1.169–1.769) 0.001 1.293 (1.044–1.602) 0.019
Vascular invasion (yes vs no) 1.836 (1.478–2.280) 0.000 1.279 (0.998–1.637) 0.052
Tumor differentiation 1.440 (1.184–1.752) 0.000 1.293 (1.056–1.584) 0.013
TNM (III–IV vs I–II) 1.630 (1.364–1.949) 0.000 1.208 (0.951–1.535) 0.121
LNM (yes vs no) 1.594 (1.124–2.261) 0.009 1.509 (1.049–2.171) 0.027
PRAF2 expression (high vs low) 1.256 (1.052–1.499) 0.011 1.244 (1.039–1.498) 0.017

Notes: Bold values indicate statistically significant values (p<0.05)

Abbreviations: AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; LNM, Lymph node metastasis; N/A, not applicable; PRAF2, prenylated Rab acceptor 1 domain family member 2.